Trial Profile
A Phase IIa Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 06 Mar 2017 The primary endpoint has been amended to include the safety endpoints as well - Participants Experiencing One or More Adverse Events and Participants Discontinuing Study Drug Due to an AE
- 15 Jun 2013 Results presented at the 14th Annual Congress of the European League Against Rheumatism.
- 08 Mar 2013 Planned number of patients changed from 244 to 247 as reported by Clinical Trials Registry - India.